De Simone C, Famularo G, Tzantzoglou S, Moretti S, Jirillo E
Malattie Infettive, University of L'Aquila, Italy.
Int J Immunopharmacol. 1991;13 Suppl 1:19-27. doi: 10.1016/0192-0561(91)90120-v.
Inosine pranobex (InPx) could prove a valuable and innovative approach to the treatment of HIV-infected patients, since InPx administration has been shown in two multicenter trials to effectively delay the progression of HIV infection to overt AIDS. However, further studies are strongly required to optimize both the dosage of inosine pranobex and the administration schedules. Furthermore, clinical trials evaluating combination therapy of HIV infection with both InPx and zidovudine should ultimately provide an important advance in the management of HIV-infected patients. Our finding that concomitantly administered InPx to zidovudine-receiving patients increased the plasma levels of zidovudine as well as prolonged zidovudine mean half-life during InPx treatment suggests several potential advantages of the combination treatment with both InPx and zidovudine, such as a need for lower zidovudine dosage and a longer interval period between administering zidovudine to obtain sustained plasma levels as well as a potential to enhance residue immune function resulting from inosine pranobex treatment.
异丙肌苷（InPx）可能是治疗HIV感染患者的一种有价值且创新的方法，因为在两项多中心试验中已表明，给予InPx可有效延缓HIV感染进展为明显的艾滋病。然而，迫切需要进一步研究以优化异丙肌苷的剂量和给药方案。此外，评估InPx与齐多夫定联合治疗HIV感染的临床试验最终应能在HIV感染患者的管理方面取得重要进展。我们的研究发现，在接受齐多夫定治疗的患者中同时给予InPx，可提高齐多夫定的血浆水平，并在InPx治疗期间延长齐多夫定的平均半衰期，这表明InPx与齐多夫定联合治疗具有几个潜在优势，例如可能需要更低的齐多夫定剂量、在给予齐多夫定以获得持续血浆水平时可延长给药间隔时间，以及因异丙肌苷治疗而增强残余免疫功能的潜力。
